MKLN1

Across TCGA pan-cancer cohorts, MKLN1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MKLN1 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher MKLN1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MKLN1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

GBM, LUAD, and UCEC are the cancer types where MKLN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.632	0.892	.006	9	view →
LUAD	DFS	Median	All	0.486	0.740	.009	7	view →
UCEC	OS	Median	All	0.968	1.000	.046	2	view →
PDAC	DFS	Tertile	III,IV	0.510	0.221	.035	2	view →
LSCC	OS	Quartile	II,III,IV	0.930	0.626	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MKLN1–GBM (OS)

Open the GBM breakdown →